SCHEMBL25342452

SCHEMBL25342452

N#CC(F)C(=O)c1ccc(Cl)cc1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
CES2 O00748 3/20 0.45
CES1 P23141 3/20 0.45
ALOX15 P16050 1/20 0.43
TSHR P16473 1/20 0.43
CA1 P00915 2/20 0.42
CA2 P00918 2/20 0.42
ALDH1A1 P00352 2/20 0.41
L3MBTL1 Q9Y468 2/20 0.41
NPC1 O15118 1/20 0.41
MDM2 Q00987 3/20 0.40
GSK3B P49841 3/20 0.39
SRD5A2 P31213 1/20 0.39
MAPK1 P28482 1/20 0.39
S1PR3 Q99500 1/20 0.38
KDM4E B2RXH2 1/20 0.38
LMNA P02545 1/20 0.38
MAPT P10636 1/20 0.38
RAPGEF3 O95398 2/20 0.38
TRPA1 O75762 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29237750 0.80 TDP1 (0.47) CES2CES1TSHRCA1CA2
SCHEMBL6831516 0.80 CA1 (0.50) CES2CES1ALOX15TSHRCA1
SCHEMBL740969 0.80 TDP1 (0.47) CES2CES1TSHRCA1CA2
SCHEMBL9860932 0.78 CES2 (0.46) CES2CES1ALOX15TSHRCA1
SCHEMBL1143569 0.77 CES2 (0.45) CES2CES1ALOX15TSHRCA1
SCHEMBL10361690 0.75 CES2 (0.52) CES2CES1ALOX15TSHRCA1
SCHEMBL30737578 0.74 TRPA1 (0.44) CES2CES1ALOX15TSHRCA1
SCHEMBL8022083 0.74 CES2 (0.50) CES2CES1ALOX15TSHRCA1
SCHEMBL27650390 0.74 CES2 (0.50) CES2CES1ALOX15TSHRCA1
SCHEMBL30737544 0.73 RAPGEF3 (0.44) CES2CES1ALOX15TSHRCA1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250154139-A1 PYRIDAZINONE COMPOUNDS AS TRPA1 INHIBITORS D. E. SHAW RESEARCH, LLC 2025-05-15 US disclosed
US-20250136587-A1 N3-SUBSTITUTED URACIL COMPOUNDS AS TRPA1 INHIBITORS D. E. SHAW RESEARCH, LLC 2025-05-01 US disclosed
EP-4472627-A2 N3-SUBSTITUTED URACIL COMPOUNDS AS TRPA1 INHIBITORS D.E. Shaw Research, LLC (US) 2024-12-11 EP disclosed
EP-4472624-A2 PYRIDAZINONE COMPOUNDS AS TRPA1 INHIBITORS D.E. Shaw Research, LLC (US) 2024-12-11 EP disclosed
CN-118973564-A Pyridazinone compounds as TRPA1 inhibitors D·E·萧尔研究有限责任公司 2024-11-15 CN disclosed
CN-118922185-A N3-substituted uracil compounds as TRPA1 inhibitors D·E·萧尔研究有限责任公司 2024-11-08 CN disclosed
WO-2023150592-A2 N3-SUBSTITUTED URACIL COMPOUNDS AS TRPA1 INHIBITORS D.E. SHAW RESEARCH, LLC (US) 2023-08-10 WO disclosed
WO-2023150591-A2 PYRIDAZINONE COMPOUNDS AS TRPA1 INHIBITORS D.E. SHAW RESEARCH, LLC (US) 2023-08-10 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20250136587-A1 N3-SUBSTITUTED URACIL COMPOUNDS AS TRPA1 INHIBITORS TRPA1, TRPV1, SLC28A1 CES2 1621/4885CES1 3201/4885ALOX15 734/4885
US-20250154139-A1 PYRIDAZINONE COMPOUNDS AS TRPA1 INHIBITORS TRPA1, TRPV1, TRPV5 CES2 1988/4885CES1 2806/4885ALOX15 420/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.